Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:DBTX

Decibel Therapeutics (DBTX) Stock Price, News & Analysis

Decibel Therapeutics logo

About Decibel Therapeutics Stock (NASDAQ:DBTX)

Advanced Chart

Key Stats

Today's Range
$4.90
$5.11
50-Day Range
$4.91
$5.23
52-Week Range
$1.61
$5.40
Volume
1.26 million shs
Average Volume
122,002 shs
Market Capitalization
$123.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive DBTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Decibel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DBTX Stock News Headlines

Warren Buffett Issues Cryptic Warning on U.S. Dollar
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.tc pixel
The Best Noise-Cancelling Headphones
Decibel Therapeutics' CVR Appears Around Fair Value
See More Headlines

DBTX Stock Analysis - Frequently Asked Questions

Decibel Therapeutics, Inc. (NASDAQ:DBTX) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by $0.23.

Decibel Therapeutics (DBTX) raised $100 million in an initial public offering (IPO) on Friday, February 12th 2021. The company issued 5,900,000 shares at $16.00-$18.00 per share. Citigroup, BMO Capital Markets, SVB Leerink and Barclays served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Decibel Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), Zomedica (ZOM), Wells Fargo & Company (WFC), Bank of America (BAC), JPMorgan Chase & Co. (JPM) and Abbott Laboratories (ABT).

Company Calendar

Last Earnings
11/10/2021
Today
9/15/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:DBTX
CIK
1656536
Fax
N/A
Employees
68
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($2.53)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$63.01 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-84.03%
Return on Assets
-53.90%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.03
Quick Ratio
3.03

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.28 per share
Price / Book
1.50

Miscellaneous

Outstanding Shares
25,130,000
Free Float
16,182,000
Market Cap
$123.39 million
Optionable
Not Optionable
Beta
-0.43
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:DBTX) was last updated on 9/15/2025 by MarketBeat.com Staff
From Our Partners